<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">medsovet</journal-id><journal-title-group><journal-title xml:lang="ru">Медицинский Совет</journal-title><trans-title-group xml:lang="en"><trans-title>Meditsinskiy sovet = Medical Council</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2079-701X</issn><issn pub-type="epub">2658-5790</issn><publisher><publisher-name>REMEDIUM GROUP Ltd.</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.21518/2079-701X-2020-11-224-232</article-id><article-id custom-type="elpub" pub-id-type="custom">medsovet-5774</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ДИССЕРТАНТ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>DISSERTANT</subject></subj-group></article-categories><title-group><article-title>Прогресс неинвазивной диагностики фиброза печени: обзор современных лабораторных методик</article-title><trans-title-group xml:lang="en"><trans-title>Progress of non-invasive diagnostic of liver fibrosis: review of modern laboratory methods</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-9798-9617</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Кулебина</surname><given-names>Е. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Kulebina</surname><given-names>E. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Кулебина Елена Анатольевна, педиатр, гастроэнтеролог, аспирант гастроэнтерологического отделения с гепатологической группой </p><p>119991, Москва, Ломоносовский проспект, д. 2, стр. 1</p></bio><bio xml:lang="en"><p>Elena A. Kulebina, pediatrician, gastroenterologist, Postgraduate Studient of the Department of Gastroenterology with a Hepatology Group </p><p>2, Bldg.1, Lomonosovskiy Prospect, Moscow, 119926</p></bio><email xlink:type="simple">e.kulebina@gmail.com</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-3697-4283</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Сурков</surname><given-names>А. Н.</given-names></name><name name-style="western" xml:lang="en"><surname>Surkov</surname><given-names>A. N.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Сурков Андрей Николаевич, д.м.н., заведующий гастроэнтерологическим отделением с гепатологической группой; доцент кафедры факультетской педиатрии педиатрического факультета </p><p>119991, Москва, Ломоносовский проспект, д. 2, стр. 1</p><p>117513, Москва, ул. Островитянова, д. 1, стр. 7</p></bio><bio xml:lang="en"><p>Andrey N. Surkov, Dr. of Sci. (Med.), Head of the Department of Gastroenterology with a Hepatology Group; Associate Professor of the Department of Pediatrics of the Faculty of Pediatrics </p><p>2, Bldg.1, Lomonosovskiy Prospect, Moscow, 119926</p><p>1, Ostrovityanov St., Moscow, 117997</p></bio><email xlink:type="simple">surkov@nczd.ru</email><xref ref-type="aff" rid="aff-2"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Национальный медицинский исследовательский центр здоровья детей</institution><country>Россия</country></aff><aff xml:lang="en"><institution>National Medical Research Center for Children’s Health</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>Национальный медицинский исследовательский центр здоровья детей; Российский национальный исследовательский медицинский университет им. Н.И. Пирогова</institution><country>Россия</country></aff><aff xml:lang="en"><institution>National Medical Research Center for Children’s Health; Pirogov Russian National Research Medical University</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2020</year></pub-date><pub-date pub-type="epub"><day>08</day><month>08</month><year>2020</year></pub-date><volume>0</volume><issue>11</issue><fpage>224</fpage><lpage>232</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Кулебина Е.А., Сурков А.Н., 2020</copyright-statement><copyright-year>2020</copyright-year><copyright-holder xml:lang="ru">Кулебина Е.А., Сурков А.Н.</copyright-holder><copyright-holder xml:lang="en">Kulebina E.A., Surkov A.N.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.med-sovet.pro/jour/article/view/5774">https://www.med-sovet.pro/jour/article/view/5774</self-uri><abstract><p>Диагностика фиброза и цирроза печени традиционно проводится с помощью биопсии. Тем не менее за последние десятилетия учеными во всем мире показано, что принятый «золотой стандарт диагностики» – морфологическая оценка биоптата – имеет ряд ограничений. Поиск неинвазивных техник диагностики фиброза привел к разработке множества шкал с применением лабораторных маркеров. Неинвазивные методы диагностики более безопасны для пациента по сравнению с биопсией печени. Кроме того, они могут быть проведены повторно в динамике, чтобы оценить состояние печени в течение длительного времени. Большинство доступных в настоящее время неинвазивных методик диагностики значительно дешевле принятого «золотого стандарта». Их практическое использование растет с каждым годом, и в ряде стран частота выполнения биопсии печени при вирусных гепатитах B и C неуклонно снижается благодаря развитию систем сывороточной и визуализационной диагностики. Недавние исследования свидетельствуют о том, что оценка степени фиброза неинвазивными методами является такой же точной, как и морфологическое исследование. В последние годы в качестве неинвазивной диагностики стадий фиброза печени рассматривают ряд сывороточных маркеров, среди которых наибольшее число исследований посвящено гиалуроновой кислоте, коллагену IV типа, а также их комбинации с различными общепринятыми лабораторными тестами. Новейшие неинвазивные техники в ближайшем будущем произведут значимый сдвиг парадигмы в оценке печеночного фиброза. В данном обзоре мы проанализировали широко используемые, а также экспериментальные лабораторные методики, используемые в диагностике степени фиброза печени.</p></abstract><trans-abstract xml:lang="en"><p>Fibrosis and cirrhosis are traditionally diagnosed by making a biopsy. However, in recent decades, scientists around the world have shown that the accepted “gold standard of diagnosis” – morphological assessment of biopsy – has a number of limitations. The search for non-invasive techniques to diagnose fibrosis has led to the development of many scales using laboratory indices. Non-invasive diagnostic techniques are safer for the patient than liver biopsy. In addition, they can be repeated in a dynamic to assess the condition of the liver over time. Most currently available non-invasive diagnostic techniques are considerably cheaper than the accepted “gold standard”. Their practical use is increasing every year, and in a number of countries the frequency of liver biopsies in viral hepatitis B and C is steadily decreasing due to the development of serum and imaging diagnostic systems. Recent studies show that the assessment of the degree of fibrosis by non-invasive methods is as accurate as a morphological study. In recent years, a number of serum markers have been considered as non-invasive diagnostics of the stages of liver fibrosis, among which the largest number of studies are devoted to hyaluronic acid, type IV collagen, and their combination with various common laboratory tests. The latest non-invasive techniques will make a significant paradigm shift in the evaluation of liver fibrosis in the near future. In this review we have analyzed widely used as well as experimental laboratory techniques used in the diagnosis of liver fibrosis.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>фиброз печени</kwd><kwd>гиалуроновая кислота</kwd><kwd>коллагены</kwd><kwd>гликопротеин YKL-40</kwd><kwd>ламинин</kwd><kwd>цитокины</kwd><kwd>коэффициент де Ритиса</kwd><kwd>APRI</kwd><kwd>FIB-4</kwd><kwd>индекс Форнса</kwd></kwd-group><kwd-group xml:lang="en"><kwd>Liver fibrosis</kwd><kwd>hyaluronic acid</kwd><kwd>collagens</kwd><kwd>glycoprotein YKL-40</kwd><kwd>laminin</kwd><kwd>cytokines</kwd><kwd>De Ritis Ratio</kwd><kwd>APRI</kwd><kwd>FIB-4</kwd><kwd>Forns index</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Lurie Y., Webb M., Cytter-Kuint R., Shteingart S., Lederkremer G.Z. Noninvasive diagnosis of liver fibrosis and cirrhosis. World J Gastroenterol. 2015;21(41):11567–11583. doi: 10.3748/wjg.v21.i41.11567.</mixed-citation><mixed-citation xml:lang="en">Lurie Y., Webb M., Cytter-Kuint R., Shteingart S., Lederkremer G.Z. Noninvasive diagnosis of liver fibrosis and cirrhosis. World J Gastroenterol. 2015;21(41):11567–11583. doi: 10.3748/wjg.v21.i41.11567.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Ahmad W., Ijaz B., Gull S., Asad S., Khaliq S., Jahan S. et al. A brief review on molecular, genetic and imaging techniques for HCV fibrosis evaluation. Virol J. 2011;8:53. doi: 10.1186/1743-422X-8-53.</mixed-citation><mixed-citation xml:lang="en">Ahmad W., Ijaz B., Gull S., Asad S., Khaliq S., Jahan S. et al. A brief review on molecular, genetic and imaging techniques for HCV fibrosis evaluation. Virol J. 2011;8:53. doi: 10.1186/1743-422X-8-53.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Liu T., Wang X., Karsdal M.A., Leeming D.J., Genovese F. Molecular serum markers of liver fibrosis. Biomark Insights. 2012;7:105–117. doi: 10.4137/BMI.S10009.</mixed-citation><mixed-citation xml:lang="en">Liu T., Wang X., Karsdal M.A., Leeming D.J., Genovese F. Molecular serum markers of liver fibrosis. Biomark Insights. 2012;7:105–117. doi: 10.4137/ BMI.S10009.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Castera L., Pinzani M. Biopsy and non-invasive methods for the diagnosis of liver fibrosis: does it take two to tango? Gut. 2010;59(7):861–866. doi: 10.1136/gut.2010.214650.</mixed-citation><mixed-citation xml:lang="en">Castera L., Pinzani M. Biopsy and non-invasive methods for the diagnosis of liver fibrosis: does it take two to tango? Gut. 2010;59(7):861–866. doi: 10.1136/gut.2010.214650.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Gressner O.A., Gao C. Monitoring fibrogenic progression in the liver. Clin Chim Acta. 2014;433:111–122. doi: 10.1016/j.cca.2014.02.021.</mixed-citation><mixed-citation xml:lang="en">Gressner O.A., Gao C. Monitoring fibrogenic progression in the liver. Clin Chim Acta. 2014;433:111–122. doi: 10.1016/j.cca.2014.02.021.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Adams L.A. Non-invasive diagnosis of fibrosis in NAFLD, how reliable is it? EASL postgraduate course metabolic liver disease. In: Dufour J.-F., Ratziu V., Tilg H. (eds.). The International Liver Congressä 2015. Vienna, Austria, April 22–23, 2015; 2015. 112 p. Available at: https://pdfs.semanticscholar.org/54d1/afbfc2632f6a7c5bd15373f32550a86518b1.pdf.</mixed-citation><mixed-citation xml:lang="en">Adams L.A. Non-invasive diagnosis of fibrosis in NAFLD, how reliable is it? EASL postgraduate course metabolic liver disease. In: Dufour J.-F., Ratziu V., Tilg H. (eds.). The International Liver Congressä 2015. Vienna, Austria, April 22–23, 2015; 2015. 112 p. Available at: https://pdfs.semanticscholar.org/54d1/afbfc2632f6a7c5bd15373f32550a86518b1.pdf.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">McPherson S., Stewart S.F., Henderson E., Burt A.D., Day C.P. Simple noninvasive fibrosis scoring systems can reliably exclude advanced fibrosis in patients with non-alcoholic fatty liver disease. Gut. 2010;59(9):1265–1269. doi: 10.1136/gut.2010.216077.</mixed-citation><mixed-citation xml:lang="en">McPherson S., Stewart S.F., Henderson E., Burt A.D., Day C.P. Simple noninvasive fibrosis scoring systems can reliably exclude advanced fibrosis in patients with non-alcoholic fatty liver disease. Gut. 2010;59(9):1265–1269. doi: 10.1136/gut.2010.216077.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Lin Z.H., Xin Y.N., Dong Q.J., Wang Q., Jiang X.J., Zhan S.H. et al. Performance of the aspartate aminotransferase-to-platelet ratio index for the staging of hepatitis C-related fibrosis: an updated meta-analysis. Hepatology. 2011;53(3):726–736. doi: 10.1002/hep.24105.</mixed-citation><mixed-citation xml:lang="en">Lin Z.H., Xin Y.N., Dong Q.J., Wang Q., Jiang X.J., Zhan S.H. et al. Performance of the aspartate aminotransferase-to-platelet ratio index for the staging of hepatitis C-related fibrosis: an updated meta-analysis. Hepatology. 2011;53(3):726–736. doi: 10.1002/hep.24105.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Zhu X., Wang L.C., Chen E.Q., Chen X.B., Chen L.Y., Liu L. et al. Prospective evaluation of FibroScan for the diagnosis of hepatic fibrosis compared with liver biopsy/AST platelet ratio index and FIB-4 in patients with chronic HBV infection. Dig Dis Sci. 2011;56(9):2742–2749. doi: 10.1007/s10620-011-1659-1.</mixed-citation><mixed-citation xml:lang="en">Zhu X., Wang L.C., Chen E.Q., Chen X.B., Chen L.Y., Liu L. et al. Prospective evaluation of FibroScan for the diagnosis of hepatic fibrosis compared with liver biopsy/AST platelet ratio index and FIB-4 in patients with chronic HBV infection. Dig Dis Sci. 2011;56(9):2742–2749. doi: 10.1007/s10620-011-1659-1.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Usluer G., Erben N., Aykin N., Dagli O., Aydogdu O., Barut S. et al. Comparison of non-invasive fibrosis markers and classical liver biopsy in chronic hepatitis C. Eur J Clin Microbiol Infect Dis. 2012;31:1873–1878. doi: 10.1007/s10096-011-1513-6.</mixed-citation><mixed-citation xml:lang="en">Usluer G., Erben N., Aykin N., Dagli O., Aydogdu O., Barut S. et al. Comparison of non-invasive fibrosis markers and classical liver biopsy in chronic hepatitis C. Eur J Clin Microbiol Infect Dis. 2012;31:1873–1878. doi: 10.1007/s10096-011-1513-6.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Martin J., Khatri G., Gopal P., Singal A.G. Accuracy of ultrasound and noninvasive markers of fibrosis to identify patients with cirrhosis. Dig Dis Sci. 2015;60(6):1841–1847. doi: 10.1007/s10620-015-3531-1.</mixed-citation><mixed-citation xml:lang="en">Martin J., Khatri G., Gopal P., Singal A.G. Accuracy of ultrasound and noninvasive markers of fibrosis to identify patients with cirrhosis. Dig Dis Sci. 2015;60(6):1841–1847. doi: 10.1007/s10620-015-3531-1.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Haseltine E.L., Penney M.S., George S., Kieffer T.L. Successful treatment with telaprevir-based regimens for chronic hepatitis C results in significant improvements to serum markers of liver fibrosis. J Viral Hepat. 2015;22(9):701–707. doi: 10.1111/jvh.12382.</mixed-citation><mixed-citation xml:lang="en">Haseltine E.L., Penney M.S., George S., Kieffer T.L. Successful treatment with telaprevir-based regimens for chronic hepatitis C results in significant improvements to serum markers of liver fibrosis. J Viral Hepat. 2015;22(9):701–707. doi: 10.1111/jvh.12382.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Papastergiou V., Stampori M., Lisgos P., Pselas C., Prodromidou K., Karatapanis S. Durability of a sustained virological response, late clinical sequelae, and long-term changes in aspartate aminotransferase to the platelet ratio index after successful treatment with peginterferon/ribavirin for chronic hepatitis C: a prospective study. Eur J Gastroenterol Hepatol. 2013;25(7):798–805. doi: 10.1097/MEG.0b013e32835eb8bf.</mixed-citation><mixed-citation xml:lang="en">Papastergiou V., Stampori M., Lisgos P., Pselas C., Prodromidou K., Karatapanis S. Durability of a sustained virological response, late clinical sequelae, and long-term changes in aspartate aminotransferase to the platelet ratio index after successful treatment with peginterferon/ribavirin for chronic hepatitis C: a prospective study. Eur J Gastroenterol Hepatol. 2013;25(7):798–805. doi: 10.1097/MEG.0b013e32835eb8bf.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Tapper E.B., Krajewski K., Lai M., Challies T., Kane R., Afdhal N., Lau D. Simple non-invasive biomarkers of advanced fibrosis in the evaluation of non-alcoholic fatty liver disease. Gastroenterol Rep (Oxf). 2014;2(4):276– 280. doi: 10.1093/gastro/gou034.</mixed-citation><mixed-citation xml:lang="en">Tapper E.B., Krajewski K., Lai M., Challies T., Kane R., Afdhal N., Lau D. Simple non-invasive biomarkers of advanced fibrosis in the evaluation of non-alcoholic fatty liver disease. Gastroenterol Rep (Oxf). 2014;2(4):276– 280. doi: 10.1093/gastro/gou034.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Xiao G., Yang J., Yan L. Comparison of diagnostic accuracy of aspartate aminotransferase to platelet ratio index and fibrosis-4 index for detecting liver fibrosis in adult patients with chronic hepatitis B virus infection: a systemic review and meta-analysis. Hepatology. 2015;61(1):292–302. doi: 10.1002/hep.27382.</mixed-citation><mixed-citation xml:lang="en">Xiao G., Yang J., Yan L. Comparison of diagnostic accuracy of aspartate aminotransferase to platelet ratio index and fibrosis-4 index for detecting liver fibrosis in adult patients with chronic hepatitis B virus infection: a systemic review and meta-analysis. Hepatology. 2015;61(1):292–302. doi: 10.1002/hep.27382.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Stibbe K.J., Verveer C., Francke J., Hansen B.E., Zondervan P.E., Kuipers E.J. et al. Comparison of noninvasive assessment to diagnose liver fibrosis in chronic hepatitis B and C patients. Scand J Gastroenterol. 2011;46(7– 8):962–972. doi: 10.3109/00365521.2011.574725.</mixed-citation><mixed-citation xml:lang="en">Stibbe K.J., Verveer C., Francke J., Hansen B.E., Zondervan P.E., Kuipers E.J. et al. Comparison of noninvasive assessment to diagnose liver fibrosis in chronic hepatitis B and C patients. Scand J Gastroenterol. 2011;46(7–8):962–972. doi: 10.3109/00365521.2011.574725.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Шептулина А.Ф., Широкова Е.Н., Ивашкин В.Т. Неинвазивные методы диагностики фиброза печени у больных первичным билиарным циррозом и первичным склерозирующим холангитом: роль непрямых сывороточных маркеров. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2016;26(3):52–63. doi: 10.22416/1382-4376-2016-26-3-52-63.</mixed-citation><mixed-citation xml:lang="en">Sheptulina A.F., Shirokova Ye.N., Ivashkin V.T. Noninvasive diagnostic methods of liver fibrosis in patients with primary biliary cirrhosis and primary sclerosing cholangitis: role of indirect serological markers. Rossiyskiy zhurnal gastroehnterologii, gepatologii, koloproktologii = Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2016;26(3):52–63. (In Russ.) doi: 10.22416/1382-4376-2016-26-3-52-63.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Poynard T., Ngo Y., Munteanu M., Thabut D., Ratziu V. Noninvasive Markers of Hepatic Fibrosis in Chronic Hepatitis B. Curr Hepat Rep. 2011;10(2):87– 97. doi: 10.1007/s11901-011-0096-0.</mixed-citation><mixed-citation xml:lang="en">Poynard T., Ngo Y., Munteanu M., Thabut D., Ratziu V. Noninvasive Markers of Hepatic Fibrosis in Chronic Hepatitis B. Curr Hepat Rep. 2011;10(2):87– 97. doi: 10.1007/s11901-011-0096-0.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Poynard T., Moussalli J., Munteanu M., Thabut D., Lebray P., Rudler M. et al. Slow regression of liver fibrosis presumed by repeated biomarkers after virological cure in patients with chronic hepatitis C. J Hepatol. 2013;59(4):675–683. doi: 10.1016/j.jhep.2013.05.015.</mixed-citation><mixed-citation xml:lang="en">Poynard T., Moussalli J., Munteanu M., Thabut D., Lebray P., Rudler M. et al. Slow regression of liver fibrosis presumed by repeated biomarkers after virological cure in patients with chronic hepatitis C. J Hepatol. 2013;59(4):675–683. doi: 10.1016/j.jhep.2013.05.015.</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Chou R., Wasson N. Blood tests to diagnose fibrosis or cirrhosis in patients with chronic hepatitis C virus infection: a systematic review. Ann Intern Med. 2013;158(11):807–820. doi: 10.7326/0003-4819-158-11-201306040-00005.</mixed-citation><mixed-citation xml:lang="en">Chou R., Wasson N. Blood tests to diagnose fibrosis or cirrhosis in patients with chronic hepatitis C virus infection: a systematic review. Ann Intern Med. 2013;158(11):807–820. doi: 10.7326/0003-4819-158-11-201306040-00005.</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Щекотова А.П., Булатова И.А., Ройтман А.П. Чувствительность и специфичность определения гиалуроновой кислоты, коэффициента де Ритиса и васкулоэндотелиального фактора роста для диагностики хронического гепатита и цирроза печени. Пермский медицинский журнал. 2013;(4):84–90. Режим доступа: https://elibrary.ru/item.asp?id=20226896.</mixed-citation><mixed-citation xml:lang="en">Schekotova A.P., Bulatova I.A., Roitman A.P. Sensitivity and specificity of hyaluronic acid, de ritis coefficient and vasculoendothelial growth factor determination for diagnosis of chronic hepatitis and hepatic cirrhosis. Perm Medical Journal. 2013;(4):84–90. (In Russ.) Available at: https://elibrary.ru/item.asp?id=20226896.</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Boursier J., Brochard C., Bertrais S., Michalak S., Gallois Y., Fouchard-Hubert I. et al. Combination of blood tests for significant fibrosis and cirrhosis improves the assessment of liver-prognosis in chronic hepatitis C. Aliment Pharmacol Ther. 2014;40(2):178–188. doi: 10.1111/apt.12813.</mixed-citation><mixed-citation xml:lang="en">Boursier J., Brochard C., Bertrais S., Michalak S., Gallois Y., Fouchard-Hubert I. et al. Combination of blood tests for significant fibrosis and cirrhosis improves the assessment of liver-prognosis in chronic hepatitis C. Aliment Pharmacol Ther. 2014;40(2):178–188. doi: 10.1111/apt.12813.</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Valva P., Casciato P., Diaz Carrasco J.M., Gadano A., Galdame O., Galoppo M.C. et al. The role of serum biomarkers in predicting fibrosis progression in pediatric and adult hepatitis C virus chronic infection. PLoS One. 2011;6(8):e23218. doi: 10.1371/journal.pone.0023218.</mixed-citation><mixed-citation xml:lang="en">Valva P., Casciato P., Diaz Carrasco J.M., Gadano A., Galdame O., Galoppo M.C. et al. The role of serum biomarkers in predicting fibrosis progression in pediatric and adult hepatitis C virus chronic infection. PLoS One. 2011;6(8):e23218. doi: 10.1371/journal.pone.0023218.</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">European Association for Study of Liver; Asociacion Latinoamericana para el Estudio del Higado. EASL-ALEH Clinical Practice Guidelines: Noninvasive tests for evaluation of liver disease severity and prognosis. Journal of Hepatology. 2015;63(1):237–264. doi: 10.1016/j.jhep.2015.04.006.</mixed-citation><mixed-citation xml:lang="en">European Association for Study of Liver; Asociacion Latinoamericana para el Estudio del Higado. EASL-ALEH Clinical Practice Guidelines: Non invasive tests for evaluation of liver disease severity and prognosis. Journal of Hepatology. 2015;63(1):237–264. doi: 10.1016/j.jhep.2015.04.006.</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Li F., Zhu C.L., Zhang H., Huang H., Wei Q., Zhu X., Cheng X.Y. Role of hyaluronic acid and laminin as serum markers for predicting significant fibrosis in patients with chronic hepatitis B. Braz J Infect Dis. 2012;16(1):9–14. doi: 10.1016/S1413-8670(12)70267-2.</mixed-citation><mixed-citation xml:lang="en">Li F., Zhu C.L., Zhang H., Huang H., Wei Q., Zhu X., Cheng X.Y. Role of hyaluronic acid and laminin as serum markers for predicting significant fibrosis in patients with chronic hepatitis B. Braz J Infect Dis. 2012;16(1):9–14. doi: 10.1016/S1413-8670(12)70267-2.</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Lavallard V.J., Bonnafous S., Patouraux S., Saint-Paul M.C., Rousseau D., Anty R. et al. Serum markers of hepatocyte death and apoptosis are non invasive biomarkers of severe fibrosis in patients with alcoholic liver disease. PLoS One. 2011;6(3):e17599. doi: 10.1371/journal.pone.0017599.</mixed-citation><mixed-citation xml:lang="en">Lavallard V.J., Bonnafous S., Patouraux S., Saint-Paul M.C., Rousseau D., Anty R. et al. Serum markers of hepatocyte death and apoptosis are non invasive biomarkers of severe fibrosis in patients with alcoholic liver disease. PLoS One. 2011;6(3):e17599. doi: 10.1371/journal.pone.0017599.</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">Liu X., Wan X., Li Z., Lin C., Zhan Y., Lu X. Golgi protein 73(GP73), a useful serum marker in liver diseases. Clin Chem Lab Med. 2011;49(8):1311–1316. doi: 10.1515/CCLM.2011.640.</mixed-citation><mixed-citation xml:lang="en">Liu X., Wan X., Li Z., Lin C., Zhan Y., Lu X. Golgi protein 73(GP73), a useful serum marker in liver diseases. Clin Chem Lab Med. 2011;49(8):1311–1316. doi: 10.1515/CCLM.2011.640.</mixed-citation></citation-alternatives></ref><ref id="cit28"><label>28</label><citation-alternatives><mixed-citation xml:lang="ru">Morota K., Nakagawa M., Sekiya R., Hemken P.M., Sokoll L.J., Elliott D. et al. A comparative evaluation of Golgi protein-73, fucosylated hemopexin, α-fetoprotein, and PIVKAII in the serum of patients with chronic hepatitis, cirrhosis, and hepatocellular carcinoma. Clin Chem Lab Med. 2011;49(4):711–718. doi: 10.1515/CCLM.2011.097.</mixed-citation><mixed-citation xml:lang="en">Morota K., Nakagawa M., Sekiya R., Hemken P.M., Sokoll L.J., Elliott D. et al. A comparative evaluation of Golgi protein-73, fucosylated hemopexin, α-fetoprotein, and PIVKAII in the serum of patients with chronic hepatitis, cirrhosis, and hepatocellular carcinoma. Clin Chem Lab Med. 2011;49(4):711–718. doi: 10.1515/CCLM.2011.097.</mixed-citation></citation-alternatives></ref><ref id="cit29"><label>29</label><citation-alternatives><mixed-citation xml:lang="ru">Булатова И.А., Щекотова А.П., Насибуллина Н.И., Падучева С.В., Щекотов В.В. Лабораторные маркеры поражения печени при хроническом гепатите C. Современные технологии в медицине. 2017;9(3):87–92. Режим доступа: https://readera.ru/14317125.</mixed-citation><mixed-citation xml:lang="en">Bulatova I.А., Shchyokotova А.P., Nasibullina N.I., Paducheva S.V., Shchyokotov V.V. Laboratory markers of liver damage in chronic hepatitis C. Sovremennye tekhnologii v meditsine = Modern Technologies in Medicine. 2017;9(3):87–92. (In Russ.) Available at: https://readera.ru/14317125.</mixed-citation></citation-alternatives></ref><ref id="cit30"><label>30</label><citation-alternatives><mixed-citation xml:lang="ru">Aoki Y., Sugiyama M., Murata K., Yoshio S., Kurosaki M., Hashimoto S. et al. Association of serum IFN-λ3 with inflammatory and fibrosis markers in patients with chronic hepatitis C virus infection. J Gastroenterol. 2015;50(8):894–902. doi: 10.1007/s00535-014-1023-2.</mixed-citation><mixed-citation xml:lang="en">Aoki Y., Sugiyama M., Murata K., Yoshio S., Kurosaki M., Hashimoto S. et al. Association of serum IFN-λ3 with inflammatory and fibrosis markers in patients with chronic hepatitis C virus infection. J Gastroenterol. 2015;50(8):894–902. doi: 10.1007/s00535-014-1023-2.</mixed-citation></citation-alternatives></ref><ref id="cit31"><label>31</label><citation-alternatives><mixed-citation xml:lang="ru">Cheung K.J., Tilleman K., Deforce D., Colle I., Moreno C., Gustot T., Van Vlierberghe H. Usefulness of a novel serum proteome-derived index FI-PRO (fibrosis-protein) in the prediction of fibrosis in chronic hepatitis C. Eur J Gastroenterol Hepatol. 2011;23(8):701–710. doi: 10.1097/MEG.0b013e3283471b74.</mixed-citation><mixed-citation xml:lang="en">Cheung K.J., Tilleman K., Deforce D., Colle I., Moreno C., Gustot T., Van Vlierberghe H. Usefulness of a novel serum proteome-derived index FI-PRO (fibrosis-protein) in the prediction of fibrosis in chronic hepatitis C. Eur J Gastroenterol Hepatol. 2011;23(8):701–710. doi: 10.1097/MEG.0b013e3283471b74.</mixed-citation></citation-alternatives></ref><ref id="cit32"><label>32</label><citation-alternatives><mixed-citation xml:lang="ru">Ho A.S., Cheng C.C., Lee S.C., Liu M.L., Lee J.Y., Wang W.M., Wang C.C. Novel biomarkers predict liver fibrosis in hepatitis C patients: alpha 2 macroglobulin, vitamin D binding protein and apolipoprotein AI. J Biomed Sci. 2010;17(1):58. doi: 10.1186/1423-0127-17-58.</mixed-citation><mixed-citation xml:lang="en">Ho A.S., Cheng C.C., Lee S.C., Liu M.L., Lee J.Y., Wang W.M., Wang C.C. Novel biomarkers predict liver fibrosis in hepatitis C patients: alpha 2 macroglobulin, vitamin D binding protein and apolipoprotein AI. J Biomed Sci. 2010;17(1):58. doi: 10.1186/1423-0127-17-58.</mixed-citation></citation-alternatives></ref><ref id="cit33"><label>33</label><citation-alternatives><mixed-citation xml:lang="ru">Ito K., Kuno A., Ikehara Y., Sugiyama M., Saito H., Aoki Y. et al. LecT-Hepa, a glyco-marker derived from multiple lectins, as a predictor of liver fibrosis in chronic hepatitis C patients. Hepatology. 2012;56(4):1448–1456. doi: 10.1002/hep.25815.</mixed-citation><mixed-citation xml:lang="en">Ito K., Kuno A., Ikehara Y., Sugiyama M., Saito H., Aoki Y. et al. LecT-Hepa, a glyco-marker derived from multiple lectins, as a predictor of liver fibrosis in chronic hepatitis C patients. Hepatology. 2012;56(4):1448– 1456. doi: 10.1002/hep.25815.</mixed-citation></citation-alternatives></ref><ref id="cit34"><label>34</label><citation-alternatives><mixed-citation xml:lang="ru">Qu Y., Gao C.F., Zhou K., Zhao Y.P., Xu M.Y., Lu L.G. Serum N-glycomic markers in combination with panels improves the diagnosis of chronic hepatitis B. Ann Hepatol. 2012;11(2):202–212. Available at: https://europepmc.org/article/med/22345337.</mixed-citation><mixed-citation xml:lang="en">Qu Y., Gao C.F., Zhou K., Zhao Y.P., Xu M.Y., Lu L.G. Serum N-glycomic markers in combination with panels improves the diagnosis of chronic hepatitis B. Ann Hepatol. 2012;11(2):202–212. Available at: https://europepmc.org/article/med/22345337.</mixed-citation></citation-alternatives></ref><ref id="cit35"><label>35</label><citation-alternatives><mixed-citation xml:lang="ru">Cho H.J., Kim S.S., Ahn S.J., Park J.H., Kim D.J., Kim Y.B. et al. Serum transferrin as a liver fibrosis biomarker in patients with chronic hepatitis B. Clin Mol Hepatol. 2014;20(4):347–354. doi: 10.3350/cmh.2014.20.4.347.</mixed-citation><mixed-citation xml:lang="en">Cho H.J., Kim S.S., Ahn S.J., Park J.H., Kim D.J., Kim Y.B. et al. Serum transferrin as a liver fibrosis biomarker in patients with chronic hepatitis B. Clin Mol Hepatol. 2014;20(4):347–354. doi: 10.3350/cmh.2014.20.4.347.</mixed-citation></citation-alternatives></ref><ref id="cit36"><label>36</label><citation-alternatives><mixed-citation xml:lang="ru">Gangadharan B., Antrobus R., Chittenden D., Rossa J., Bapat M., Klenerman P. et al. New approaches for biomarker discovery: the search for liver fibrosis markers in hepatitis C patients. J Proteome Res. 2011;10(5):2643–2650. doi: 10.1021/pr101077c.</mixed-citation><mixed-citation xml:lang="en">Gangadharan B., Antrobus R., Chittenden D., Rossa J., Bapat M., Klenerman P. et al. New approaches for biomarker discovery: the search for liver fibrosis markers in hepatitis C patients. J Proteome Res. 2011;10(5):2643– 2650. doi: 10.1021/pr101077c.</mixed-citation></citation-alternatives></ref><ref id="cit37"><label>37</label><citation-alternatives><mixed-citation xml:lang="ru">Du S., Mao Y., Tong J., Li F., Che L., Li S. et al. A novel liver function evaluation system using radiopharmacokinetic modeling of technetium-99m-DTPA-galactosyl human serum albumin. Nucl Med Commun. 2013;34(9):893– 899. doi: 10.1097/MNM.0b013e328362e7c7.</mixed-citation><mixed-citation xml:lang="en">Du S., Mao Y., Tong J., Li F., Che L., Li S. et al. A novel liver function evaluation system using radiopharmacokinetic modeling of technetium-99m-DTPA-galactosyl human serum albumin. Nucl Med Commun. 2013;34(9):893– 899. doi: 10.1097/MNM.0b013e328362e7c7.</mixed-citation></citation-alternatives></ref><ref id="cit38"><label>38</label><citation-alternatives><mixed-citation xml:lang="ru">Benyair R., Kondratyev M., Veselkin E., Tolchinsky S., Shenkman M., Lurie Y., Lederkremer G.Z. Constant serum levels of secreted asialoglycoprotein receptor sH2a and decrease with cirrhosis. World J Gastroenterol. 2011;17(48):5305–5309. doi: 10.3748/wjg.v17.i48.5305.</mixed-citation><mixed-citation xml:lang="en">Benyair R., Kondratyev M., Veselkin E., Tolchinsky S., Shenkman M., Lurie Y., Lederkremer G.Z. Constant serum levels of secreted asialoglycoprotein receptor sH2a and decrease with cirrhosis. World J Gastroenterol. 2011;17(48):5305–5309. doi: 10.3748/wjg.v17.i48.5305.</mixed-citation></citation-alternatives></ref><ref id="cit39"><label>39</label><citation-alternatives><mixed-citation xml:lang="ru">Veselkin E., Kondratyev M., Lurie Y., Ron E., Santo M., Reif S. et al. A secreted form of the asialoglycoprotein receptor, sH2a, as a novel potential noninvasive marker for liver fibrosis. PLoS One. 2011;6(11):e27210. doi: 10.1371/journal.pone.0027210.</mixed-citation><mixed-citation xml:lang="en">Veselkin E., Kondratyev M., Lurie Y., Ron E., Santo M., Reif S. et al. A secreted form of the asialoglycoprotein receptor, sH2a, as a novel potential noninvasive marker for liver fibrosis. PLoS One. 2011;6(11):e27210. doi: 10.1371/journal.pone.0027210.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
